NRIX / Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, comb more_horizontal

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compare more_horizontal

On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid t more_horizontal

Nurix Therapeutics, Inc. (NRIX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong a more_horizontal

Nurix Therapeutics, Inc. (NRIX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong a more_horizontal

Nurix Therapeutics, Inc. (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prep more_horizontal

Nurix Therapeutics, Inc. (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This m more_horizontal

The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medi more_horizontal